Almac, MGB Biopharma partner to produce MGB-BP3 gram positive antibacterial compound MGB Biopharma and Almac’s Sciences Business Unit have entered into a collaboration where Almac will manufacture the creation of their lead gram positive antibacterial substance MGB-BP3 http://www.prednisolone.org/contact-us . The compound can be a DNA minor groove binder and is currently in pre-clinical advancement with IND submitting targeted for Q3 2012. CEO Dr Miroslav Ravic said ‘We were rapidly impressed with the strategy taken by Almac plus they have already shown an intuitive knowledge of what it requires to support small businesses like ours. We anticipate a continued fruitful relationship’. Related StoriesTumour DNA in the blood can accurately monitor malignancy in actual timeCologuard stool DNA test: A precise screening option for Alaska Native people who have colorectal cancerCancer DNA in individual's bloodstream could help deliver personalized treatment for liver cancerRick Dyer, VP Procedures, Almac further commented ‘Almac has a wealth of expertise in early stage clinical advancement and we are delighted to undertake this phase of work for MGB Biopharma and wish this is the first of many successful tasks between our businesses.’ Following on from their experience in early phase and steady development in late phase clinical development, Almac announced a capacity growth within its API service recently, leveraging its API and Medicine Product integrated offering even more.